Background: To investigate the association between proton pump inhibitor (PPI) exposure and a risk of type 2 diabetes mellitus (T2DM) among patients with upper gastrointestinal disease (UGID). Method: We conducted a case−control study from Taiwan’s National Health Insurance Research Database between 1998 and 2013. A total of 20,940 patients with T2DM and 20,940 controls were included. The dose of PPIs was categorized according to the cumulative defined daily dose (cDDD). The risk of T2DM was assessed using conditional logistic regression analysis. Result: Compared with cDDD ≤ 30, higher dosage of PPI exposure was associated with an increased risk of T2DM development: cDDD 31−120 (odds ratio [OR]: 1.20, 95% confidence interval [CI]: 1.13−1.26); cDDD 121−365 (OR: 1.26, 95% CI: 1.19−1.33); and cDDD > 365 (OR: 1.34, 95% CI: 1.23−1.46). Subgroup analysis of individual PPI showed that pantoprazole (OR: 1.14, 95% CI: 1.07−1.21), lansoprazole (OR: 1.08, 95% CI: 1.03−1.12), and omeprazole (OR: 1.11, 95% CI: 1.06−1.16) have a significantly higher risk of T2DM development. Conclusions: A dose-dependent increased risk of T2DM was found among patients with UGID using higher doses of PPIs compared with those with lower doses of these drugs. Further studies are necessary to investigate the underlying pathophysiology of PPIs and T2DM.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316003 | PMC |
http://dx.doi.org/10.3390/ijerph19148739 | DOI Listing |
Adv Ther
January 2025
Department of Endocrinology and Nutrition, Hospital Universitari de Bellvitge-IDIBELL, C/de la Feixa Llarga S/N, 08907, Hospitalet de Llobregat, Barcelona, Spain.
Introduction: Obesity and its complications are associated with high morbidity/mortality and a significant healthcare cost burden in Spain. It is therefore essential to know the potential clinical and economic benefits of reducing obesity. The objective of this study is to predict the decrease in rates of onset of potential complications associated with obesity and the cost savings after a weight loss of 15% over 10 years in Spain.
View Article and Find Full Text PDFBMC Pulm Med
January 2025
Department of Public Health, People's Hospital of Nanchuan, Chongqing, 408400, People's Republic of China.
Background: The features of community-acquired pneumonia (CAP) patients with type 2 diabetes mellitus (T2DM) differ from those without. This study aims to spot a routinely tested parameter with discriminative, predictive and prognostic value to enhance CURB-65's prognostic accuracy in CAP patients with T2DM.
Methods: We retrospectively studied consecutive CAP patients from 2020 to 2021, comparing laboratory parameters between patients with and without T2DM.
J Diabetes Complications
December 2024
Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China; Beijing Key Laboratory of Diabetes Research and Care, Beijing 101149, China. Electronic address:
Background: Left ventricular hypertrophy (LVH) is an important and common pathologic change in the heart of patients with diabetes mellitus. Microvascular complications have been reported to be involved in the development and process of LVH. This study aimed to explore the association between diabetic microvascular complications and LVH in patients with type 2 diabetes mellitus (T2DM).
View Article and Find Full Text PDFAm J Transl Res
December 2024
Department of Infectious Diseases, Shanghai Fifth People's Hospital Shanghai 200240, China.
Objective: To investigate the association between the basic and clinical characteristics of patients with type 2 diabetes mellitus (T2DM) and their susceptibility to Klebsiella pneumoniae colonization (KPC). Additionally, a clinical prediction model was developed to identify high-risk patients for KPC.
Methods: Data from 486 T2DM patients who visited Shanghai Fifth People's Hospital from December 2020 to December 2022 were retrospectively collected.
Cureus
December 2024
Family Medicine, Najran Armed Forces Hospital, Najran, SAU.
Although observational studies have linked vitamin D deficiency to diabetes, it is unknown if taking vitamin D supplements can reduce the chance of developing type 2 diabetes mellitus (T2DM). The purpose of this systematic review is to determine whether vitamin D supplementation lowers the risk of type 2 diabetes. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to search for studies based on pre-established inclusion and exclusion criteria.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!